PDF(Pubmed)
Abstract：
UNASSIGNED: Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. Shrunken pore syndrome (SPS) is defined as eGFRcystatin C/eGFRcreatinine ratio <0.70 and predicts high CVD mortality. The Framingham Risk Score (FRS) is used to estimate an individual\'s 10-year CVD risk. This study investigated the association between FRS and eGFRcystatin C/eGFRcreatinine ratio in T2DM patients.
UNASSIGNED: Patients aged 18-80 years who were newly diagnosed with T2DM were included in this retrospective study. Ordinal logistic regression analysis was used to investigate the association between risk factors of T2DM and FRS. A Generalized Linear Model was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
UNASSIGNED: There were 270 patients included in the study. Only 27 patients (10%) met the diagnostic criteria of SPS. Ordinal logistic regression analysis showed that SPS was not correlated with FRS risk (OR = 1.99, 95%CI = 0.94-4.23, p = 0.07), whereas eGFRcystatin C/eGFRcreatinine (OR = 0.86, 95%CI = 0.77-0.97, p = 0.01) showed a significant negative association with FRS risk. Compared with eGFRcystatin C/eGFRcreatinine>0.85, eGFRcystatin C/eGFRcreatinine≤0.85 increased FRS risk (OR = 1.95, 95%CI = 1.18-3.21, p < 0.01). After adjustment for confounding factors, increased eGFRcystatin C/eGFRcreatinine ratio was associated with decreased FRS risk when considered as a continuous variable (OR = 0.87, 95%CI = 0.77-0.99, p = 0.03). The FRS risk in patients with eGFRcystatin C/eGFRcreatinine≤0.85 is 1.86 times higher than that in patients with eGFRcystatin C/eGFRcreatinine>0.85 (OR = 1.86, 95%CI = 1.08-3.21, p = 0.03).
UNASSIGNED: In the current study, no significant association between SPS and FRS was identified. However, lower eGFRcystatin C/eGFRcreatinine and eGFRcystatin C/eGFRcreatinine≤0.85 were associated with a significantly increased CVD risk in T2DM.
UNASSIGNED: Patients aged 18-80 years who were newly diagnosed with T2DM were included in this retrospective study. Ordinal logistic regression analysis was used to investigate the association between risk factors of T2DM and FRS. A Generalized Linear Model was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
UNASSIGNED: There were 270 patients included in the study. Only 27 patients (10%) met the diagnostic criteria of SPS. Ordinal logistic regression analysis showed that SPS was not correlated with FRS risk (OR = 1.99, 95%CI = 0.94-4.23, p = 0.07), whereas eGFRcystatin C/eGFRcreatinine (OR = 0.86, 95%CI = 0.77-0.97, p = 0.01) showed a significant negative association with FRS risk. Compared with eGFRcystatin C/eGFRcreatinine>0.85, eGFRcystatin C/eGFRcreatinine≤0.85 increased FRS risk (OR = 1.95, 95%CI = 1.18-3.21, p < 0.01). After adjustment for confounding factors, increased eGFRcystatin C/eGFRcreatinine ratio was associated with decreased FRS risk when considered as a continuous variable (OR = 0.87, 95%CI = 0.77-0.99, p = 0.03). The FRS risk in patients with eGFRcystatin C/eGFRcreatinine≤0.85 is 1.86 times higher than that in patients with eGFRcystatin C/eGFRcreatinine>0.85 (OR = 1.86, 95%CI = 1.08-3.21, p = 0.03).
UNASSIGNED: In the current study, no significant association between SPS and FRS was identified. However, lower eGFRcystatin C/eGFRcreatinine and eGFRcystatin C/eGFRcreatinine≤0.85 were associated with a significantly increased CVD risk in T2DM.
摘要：
心血管疾病(CVD)是2型糖尿病(T2DM)患者死亡的主要原因。缩孔综合征(SPS)定义为eGFRcystatinC/eGFR肌酐比值<0.70并预测高CVD死亡率。Framingham风险评分（FRS）用于评估个人10年CVD风险。本研究调查了T2DM患者FRS与eGFR胱抑素C/eGFR肌酐比值之间的相关性。
■新诊断为T2DM的18-80岁患者纳入本回顾性研究。采用有序logistic回归分析探讨T2DM危险因素与FRS的关系。使用广义线性模型计算比值比(OR)和95%置信区间(CI)。
■本研究包括270名患者。只有27例患者（10％）符合SPS的诊断标准。有序logistic回归分析显示SPS与FRS风险无相关性(OR=1.99,95CI=0.94~4.23,p=0.07),而eGFR胱抑素C/eGFR肌酐(OR=0.86,95CI=0.77-0.97,p=0.01)与FRS风险呈显著负相关.与eGFR胱抑素C/eGFR肌酐>0.85相比，eGFR胱抑素C/eGFR肌酐≤0.85增加FRS风险（OR=1.95，95CI=1.18-3.21，p<0.01）。在对混杂因素进行调整后，当作为连续变量时,eGFRcystatinC/eGFR肌酐比值升高与FRS风险降低相关(OR=0.87,95CI=0.77-0.99,p=0.03).eGFRcystatinC/eGFR肌酐≤0.85患者的FRS风险是eGFRcystatinC/eGFR肌酐>0.85患者的1.86倍(OR=1.86,95CI=1.08~3.21,p=0.03)。
■在当前的研究中，SPS和FRS之间未发现显著关联.然而,较低的eGFRcystatinC/eGFR肌酐和eGFRcystatinC/eGFR肌酐≤0.85与T2DM患者CVD风险显著增加相关.
■新诊断为T2DM的18-80岁患者纳入本回顾性研究。采用有序logistic回归分析探讨T2DM危险因素与FRS的关系。使用广义线性模型计算比值比(OR)和95%置信区间(CI)。
■本研究包括270名患者。只有27例患者（10％）符合SPS的诊断标准。有序logistic回归分析显示SPS与FRS风险无相关性(OR=1.99,95CI=0.94~4.23,p=0.07),而eGFR胱抑素C/eGFR肌酐(OR=0.86,95CI=0.77-0.97,p=0.01)与FRS风险呈显著负相关.与eGFR胱抑素C/eGFR肌酐>0.85相比，eGFR胱抑素C/eGFR肌酐≤0.85增加FRS风险（OR=1.95，95CI=1.18-3.21，p<0.01）。在对混杂因素进行调整后，当作为连续变量时,eGFRcystatinC/eGFR肌酐比值升高与FRS风险降低相关(OR=0.87,95CI=0.77-0.99,p=0.03).eGFRcystatinC/eGFR肌酐≤0.85患者的FRS风险是eGFRcystatinC/eGFR肌酐>0.85患者的1.86倍(OR=1.86,95CI=1.08~3.21,p=0.03)。
■在当前的研究中，SPS和FRS之间未发现显著关联.然而,较低的eGFRcystatinC/eGFR肌酐和eGFRcystatinC/eGFR肌酐≤0.85与T2DM患者CVD风险显著增加相关.
